601 related articles for article (PubMed ID: 28373570)
21. Electrical impedance myography detects dystrophin-related muscle changes in mdx mice.
Hiyoshi T; Zhao F; Baba R; Hirakawa T; Kuboki R; Suzuki K; Tomimatsu Y; O'Donnell P; Han S; Zach N; Nakashima M
Skelet Muscle; 2023 Nov; 13(1):19. PubMed ID: 37980539
[TBL] [Abstract][Full Text] [Related]
22. Systemic PPMO-mediated dystrophin expression in the Dup2 mouse model of Duchenne muscular dystrophy.
Gushchina LV; Vetter TA; Frair EC; Bradley AJ; Grounds KM; Lay JW; Huang N; Suhaiba A; Schnell FJ; Hanson G; Simmons TR; Wein N; Flanigan KM
Mol Ther Nucleic Acids; 2022 Dec; 30():479-492. PubMed ID: 36420217
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs.
Yokota T; Lu QL; Partridge T; Kobayashi M; Nakamura A; Takeda S; Hoffman E
Ann Neurol; 2009 Jun; 65(6):667-76. PubMed ID: 19288467
[TBL] [Abstract][Full Text] [Related]
24. A
Echigoya Y; Trieu N; Duddy W; Moulton HM; Yin H; Partridge TA; Hoffman EP; Kornegay JN; Rohret FA; Rogers CS; Yokota T
Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884867
[TBL] [Abstract][Full Text] [Related]
25. Exon skipping restores dystrophin expression, but fails to prevent disease progression in later stage dystrophic dko mice.
Wu B; Cloer C; Lu P; Milazi S; Shaban M; Shah SN; Marston-Poe L; Moulton HM; Lu QL
Gene Ther; 2014 Sep; 21(9):785-93. PubMed ID: 24942628
[TBL] [Abstract][Full Text] [Related]
26. Exons 45-55 Skipping Using Mutation-Tailored Cocktails of Antisense Morpholinos in the DMD Gene.
Echigoya Y; Lim KRQ; Melo D; Bao B; Trieu N; Mizobe Y; Maruyama R; Mamchaoui K; Tanihata J; Aoki Y; Takeda S; Mouly V; Duddy W; Yokota T
Mol Ther; 2019 Nov; 27(11):2005-2017. PubMed ID: 31416775
[TBL] [Abstract][Full Text] [Related]
27. Antisense pre-treatment increases gene therapy efficacy in dystrophic muscles.
Peccate C; Mollard A; Le Hir M; Julien L; McClorey G; Jarmin S; Le Heron A; Dickson G; Benkhelifa-Ziyyat S; Piétri-Rouxel F; Wood MJ; Voit T; Lorain S
Hum Mol Genet; 2016 Aug; 25(16):3555-3563. PubMed ID: 27378686
[TBL] [Abstract][Full Text] [Related]
28. Exon Skipping Therapy Using Phosphorodiamidate Morpholino Oligomers in the mdx52 Mouse Model of Duchenne Muscular Dystrophy.
Miyatake S; Mizobe Y; Takizawa H; Hara Y; Yokota T; Takeda S; Aoki Y
Methods Mol Biol; 2018; 1687():123-141. PubMed ID: 29067660
[TBL] [Abstract][Full Text] [Related]
29. Prevention of dystrophic pathology in severely affected dystrophin/utrophin-deficient mice by morpholino-oligomer-mediated exon-skipping.
Goyenvalle A; Babbs A; Powell D; Kole R; Fletcher S; Wilton SD; Davies KE
Mol Ther; 2010 Jan; 18(1):198-205. PubMed ID: 19844193
[TBL] [Abstract][Full Text] [Related]
30. Skipping multiple exons of dystrophin transcripts using cocktail antisense oligonucleotides.
Echigoya Y; Yokota T
Nucleic Acid Ther; 2014 Feb; 24(1):57-68. PubMed ID: 24380394
[TBL] [Abstract][Full Text] [Related]
31. Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice.
Jearawiriyapaisarn N; Moulton HM; Buckley B; Roberts J; Sazani P; Fucharoen S; Iversen PL; Kole R
Mol Ther; 2008 Sep; 16(9):1624-9. PubMed ID: 18545222
[TBL] [Abstract][Full Text] [Related]
32. Antisense Oligonucleotide Treatment in a Humanized Mouse Model of Duchenne Muscular Dystrophy and Highly Sensitive Detection of Dystrophin Using Western Blotting.
Maruyama R; Yokota T
Methods Mol Biol; 2021; 2224():203-214. PubMed ID: 33606217
[TBL] [Abstract][Full Text] [Related]
33. Morpholino-induced exon skipping stimulates cell-mediated and humoral responses to dystrophin in mdx mice.
Vila MC; Novak JS; Benny Klimek M; Li N; Morales M; Fritz AG; Edwards K; Boehler JF; Hogarth MW; Kinder TB; Zhang A; Mazala D; Fiorillo AA; Douglas B; Chen YW; van den Anker J; Lu QL; Hathout Y; Hoffman EP; Partridge TA; Nagaraju K
J Pathol; 2019 Jul; 248(3):339-351. PubMed ID: 30883742
[TBL] [Abstract][Full Text] [Related]
34. Restoring Dystrophin Expression with Exon 44 and 53 Skipping in the DMD Gene in Immortalized Myotubes.
Echigoya Y; Yokota T
Methods Mol Biol; 2023; 2587():125-139. PubMed ID: 36401027
[TBL] [Abstract][Full Text] [Related]
35. Optimizing exon skipping therapies for DMD.
Yokota T; Duddy W; Partridge T
Acta Myol; 2007 Dec; 26(3):179-84. PubMed ID: 18646569
[TBL] [Abstract][Full Text] [Related]
36. Bubble liposomes and ultrasound exposure improve localized morpholino oligomer delivery into the skeletal muscles of dystrophic mdx mice.
Negishi Y; Ishii Y; Shiono H; Akiyama S; Sekine S; Kojima T; Mayama S; Kikuchi T; Hamano N; Endo-Takahashi Y; Suzuki R; Maruyama K; Aramaki Y
Mol Pharm; 2014 Mar; 11(3):1053-61. PubMed ID: 24433046
[TBL] [Abstract][Full Text] [Related]
37. Bodywide skipping of exons 45-55 in dystrophic mdx52 mice by systemic antisense delivery.
Aoki Y; Yokota T; Nagata T; Nakamura A; Tanihata J; Saito T; Duguez SM; Nagaraju K; Hoffman EP; Partridge T; Takeda S
Proc Natl Acad Sci U S A; 2012 Aug; 109(34):13763-8. PubMed ID: 22869723
[TBL] [Abstract][Full Text] [Related]
38. Combination Antisense Treatment for Destructive Exon Skipping of Myostatin and Open Reading Frame Rescue of Dystrophin in Neonatal mdx Mice.
Lu-Nguyen NB; Jarmin SA; Saleh AF; Popplewell L; Gait MJ; Dickson G
Mol Ther; 2015 Aug; 23(8):1341-1348. PubMed ID: 25959011
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic Exon Skipping Through a CRISPR-Guided Cytidine Deaminase Rescues Dystrophic Cardiomyopathy in Vivo.
Li J; Wang K; Zhang Y; Qi T; Yuan J; Zhang L; Qiu H; Wang J; Yang HT; Dai Y; Song Y; Chang X
Circulation; 2021 Nov; 144(22):1760-1776. PubMed ID: 34698513
[TBL] [Abstract][Full Text] [Related]
40. [Exon skipping therapy for Duchenne muscular dystrophy by using antisense Morpholino].
Takeda S
Rinsho Shinkeigaku; 2009 Nov; 49(11):856-8. PubMed ID: 20030230
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
